Easier Listing Requirements To Attract Korean Biopharma IPOs
This article was originally published in PharmAsia News
Executive Summary
With a number of large South Korean biopharma IPOs expected this year, South Korea's benchmark Kospi and second-tier Kosdaq markets appear to be vying to attract the IPOs to their markets by easing listing regulations.